This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Jan 2011

GSK Pushes Melanoma Drugs into Ph3 Market

GSK is facilitating its study on two of its melanoma drugs to compete with other drugmakers in the melanoma arena.

GlaxoSmithKline is moving two of its melanoma drugs into late-stage trials. As Reuters reports, GSK will be moving into a late-stage melanoma arena which already includes drugs from Roche and Plexxikon as well as Bristol-Myers Squibb's ipilimumab.


The BRF113683 Phase III study compares GSK'436, a BRAF inhibitor, to dacarbazine in previously untreated patients with BRAF V600 mutated advanced or metastatic melanoma. The METRIC study compares GSK'212, a MEK inhibitor, to chemotherapy in advanced or metastatic melanoma patients with a BRAF V600 mutation.


"By focusing our research on patients with the V600 mutation, we are striving to understand how our ... inhibitors can best be used to treat patients with metastatic melanoma," said Paolo Pao

Related News